BioXcel Therapeutics, Inc. (BTAIQ)
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut. On August 27, 2026, BioXcel Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States.
The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia.
The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut. On August 27, 2026, BioXcel Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 31.31M shares outstanding
US| Name | Shares | % | Source |
|---|---|---|---|
BioXcel LLC · may incl. warrants· stale · filed Jun 2024 | 7.7M | 24.6% | 13D |
MILLENNIUM MANAGEMENT LLC | 2.1M | 6.8% | 13F |
Integrated Core Strategies (US) LLC · may incl. warrants· filed Feb 2026 | 1.8M | 5.9% | 13G |
Armistice Capital, LLC · joint filing· may incl. warrants· filed Aug 2026 | 1.6M | 5.2% | 13G |
OAKTREE CAPITAL MANAGEMENT LP | 1.4M | 4.4% | 13F |
FMR LLC · also on 13F· may incl. warrants· filed Sep 2024 | 1.1M | 3.4% | 13G |
VANGUARD CAPITAL MANAGEMENT LLC | 919.5K | 2.9% | 13F |
Adage Capital Partners, L.P. · may incl. warrants· stale · filed Feb 2024 | 465.4K | 1.5% | 13G |
Oaktree Fund Advisors, LLC | 245.6K | 0.8% | 13F |
GEODE CAPITAL MANAGEMENT, LLC | 242.3K | 0.8% | 13F |
Insiders
- Mehta VimalCEO and President, Director
- Rodriguez JavierSee Remarks
- Steinhart Richard IChief Financial Officer
- Yocca FrankChief Scientific Officer
- MACK DAVID J.Director
- O'Neill VincentSee Remarks
- Wiley Matthew T.Chief Commercial Officer
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States.
The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia.
The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut. On August 27, 2026, BioXcel Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
based on 31.31M shares outstanding
US30d Avg
256.86K
60d Avg
646.88K
90d Avg
646.88K